Nutra Pharma Corp. (NPHC) Reports Final Analysis Of ReceptoPharm's Multiple Sclerosis Drug In Microarray Studies
10/19/2005 5:12:53 PM
BOYNTON BEACH, Fla.--(BUSINESS WIRE)--March 2, 2005--Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that its contract researchers, Eno Research and Development, Inc. (ERDI) have completed their analysis of a series of microarray studies with RPI-78M in the gene expression of cells from Multiple Sclerosis (MS) patients. RPI-78M is the lead drug candidate of Nutra Pharma's minority holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating MS. ERDI measured the effect of RPI-78M on gene expression using cDNA microarray technology to identify any potentially unique changes in gene expression that may be caused by the therapy.
comments powered by